The CDC has given final approval for COVID vaccinations for young children

June 18, 2022 – COVID-19 vaccines for children from 6 months to 5 years are ready. The director of the Center for Disease Prevention (CDC), Rochelle, Valenski, PhD, today approved a unanimous recommendation from the agency’s vaccine panel to allow vaccinations to begin earlier this week.

The CDC’s Immunization Practices Advisory Committee voted 12-0 earlier today to recommend the use of Moderna COVID-19 in children aged 6 months to 5 years, as well as a 12 to 0 vote on the recommended use of Pfizer. vaccine in children aged 6 months to 4 years.

“I encourage parents and caregivers to talk to their doctor, nurse or local pharmacist with questions to learn more about the benefits of vaccinations and the importance of protecting their children by vaccinating them,” Valenski said in a statement. statement.

FDA allow vaccines on Friday for 6-month-olds, shortly after the advisory committee also unanimously recommended the photos earlier this week.

Parents and guardians already have everything they need to start vaccinating these youngest Americans with the vaccines, which are expected to begin Monday.

It is a sigh of relief for the millions of anxious parents who are waiting for this approval for their youngest children. Medical teams, from the American Academy of Pediatrics (AAP) to the American Medical Association (AMA), applauded the decision today.

“The authorization of Moderna and Pfizer-BioNTech vaccines for children over 6 months of age will extend immunization protection to the last segment of our population awaiting protection. There is still work to be done to vaccinate older children and adolescents. As of June 8, “more than 23 million children aged 5 to 17 have received two doses of the COVID vaccine. Another 26 million of this age group have not yet received any doses, “AAP said prepared statement.

“We must not give up our efforts to ensure that all families can benefit from the protection of these vaccines,” said AAP President Moira Silagi, MD, MD.

The AMA reiterated the urgency of these vaccines for young children.

According to the CDC, COVID-19 is the leading cause of death among children aged 0-19. From the beginning of pandemic, among children in the United States aged 6 months to 4 years, there were more than 2 million cases of COVID-19, more than 20,000 hospitalizations and more than 200 deaths. We urge parents to vaccinate their children against COVID-19 as soon as they meet the conditions. “Although there is vast scientific evidence that COVID-19 vaccines are safe and effective, we know that many parents and families still have questions,” said Jack Reznek, Ph.D., president of the American Medical Association. it is said in a prepared statement.

The CDC group’s vote in favor of the two COVID-19 mRNA vaccines in this age group came after two days of discussion by scientists, clinicians and other experts on the advisory committee.

The authorization for emergency use of Moderna is based on two primary doses (one quarter of the adult dose), separated by 1 month. The Pfizer vaccine is approved as a primary series of three doses (one tenth of the adult dose). The permitted dose of Pfizer vaccine is 21 days between dose 1 and dose 2, followed by 60 days between dose 2 and dose 3.

Representatives of Moderna and Pfizer reviewed the evidence for the safety and effectiveness of their products during the ACIP meeting.

Current data, for example, reveal a 50.6% effective percentage in infants and young children aged 6 to 23 months and a 36.8% effective percentage in children aged 2 to 5 years, using the CDC’s definition of effectiveness. The total number of children aged 6 months to 5 years in the assessment was 6,400, including 4,800 who received the vaccine and 1,600 who received placebo saline.

This level of efficacy is “consistent with the effectiveness in adults against Omicron,” said Rituparna Das, PhD, vice president of vaccines at Moderna.

Antibody levels after two doses of Moderna in children 6 months to 5 years of age are similar to those seen in young adults aged 18 to 24 years. Similarly, antibody levels after three doses of Pfizer vaccine were similar to those seen in people aged 16 to 24 years.

Fever, other safety considerations

Pain is the most common local reaction reported in children under 5 years of age in the Moderna vaccine study. Most symptoms are mild and last 23 to 3 days. Regarding systemic side effects, fever, irritability, crying, drowsiness and loss of appetite are most common in the group from 6 months to less than 2 years. In children from 2 to 5 years fever, headache, fatiguemuscle pain, nausea, vomitingand chills were the most common.

There was a seizure caused by fever reported 3 days after the first dose, a reaction that the researcher considered to be related to the vaccine in the Moderna study. “Approximately 6 weeks later, the child remained in the study and received two doses of the vaccine without [further] events. “

There were no cases of myocarditis or deaths reported in studies by Moderna or Pfizer.

Pain or tenderness at the injection site are the most common local reactions in the Pfizer study. In terms of systemic reactions, irritability and drowsiness are more common in children from 6 months to under 2 years. Fatigue is most common in children aged 2 to 4 years. Most symptoms are mild and go away within 1 to 2 days.

Fever has also been reported during the Pfizer trial, with most lasting about 1 day.

Related Posts

Leave a Reply

Your email address will not be published.